Pub Date : 2019-01-29DOI: 10.20471/lo.2018.46.02-03.09
Katarina Antunac, P. Suton, Sara Bilić-Knežević
Lymphopenia is a known side-eff ect of radiotherapy but, being usually asymptomatic, its clinical value is just recently being recognized in the light of immunotherapy revival. Here we present clinical and laboratory data of 9 high-risk prostate patients that underwent whole pelvis radiotherapy combined with hormonal therapy. All patients experienced haematological toxicity during their treatment, with lymphopenia being the most profound. In addition, all of them were asymptomatic as regards to observed lymphopenia. After median follow up of 17 months 8/9 patients are still receiving hormonal treatment and have no evidence of their disease. The only patient with relapse discontinued hormonal therapy upon completion of radiotherapy. Therefore, we could not show any detrimental eff ect of observed lymphopenia on the outcome of these 9 patients.
{"title":"Prognostic significance of radiation induced lymphopenia in patients with high risk prostate cancer","authors":"Katarina Antunac, P. Suton, Sara Bilić-Knežević","doi":"10.20471/lo.2018.46.02-03.09","DOIUrl":"https://doi.org/10.20471/lo.2018.46.02-03.09","url":null,"abstract":"Lymphopenia is a known side-eff ect of radiotherapy but, being usually asymptomatic, its clinical value is just recently being recognized in the light of immunotherapy revival. Here we present clinical and laboratory data of 9 high-risk prostate patients that underwent whole pelvis radiotherapy combined with hormonal therapy. All patients experienced haematological toxicity during their treatment, with lymphopenia being the most profound. In addition, all of them were asymptomatic as regards to observed lymphopenia. After median follow up of 17 months 8/9 patients are still receiving hormonal treatment and have no evidence of their disease. The only patient with relapse discontinued hormonal therapy upon completion of radiotherapy. Therefore, we could not show any detrimental eff ect of observed lymphopenia on the outcome of these 9 patients.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41325646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-29DOI: 10.20471/LO.2018.46.02-03.17
M. Bogadi, S. Kaštelan, I. Bakija, Boris Kasun
{"title":"Psihijatrijski poremećaji u bolesnika s neurofibromatozom","authors":"M. Bogadi, S. Kaštelan, I. Bakija, Boris Kasun","doi":"10.20471/LO.2018.46.02-03.17","DOIUrl":"https://doi.org/10.20471/LO.2018.46.02-03.17","url":null,"abstract":"","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.20471/LO.2018.46.02-03.17","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67598360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.20471/lo.2019.47.01.04
Katarina Antunac
When deciding on adjuvant radiotherapy in breast cancer patients, the decision is made based on the type of surgery (radical or conserving) and pathological report. In case systemic treatment is given before surgery, initial pathological report, which presents the backbone in decision making, is partly missing. Data from prospective randomized trials are lacking, and published retrospective data are inconsistent. Current guidelines are not clear for a large subset of patients. Also, guidelines and real-life data are often in discordance. This article aims to present literature data regarding the risk of locoregional relapse after neoadjuvant systemic treatment, the impact of radiotherapy on the risk of locoregional relapse, current clinical trial that is expected to give an answer in which subset of patients should adjuvant radiotherapy be performed and published clinical practice data.
{"title":"Radiotherapy after neoadjuvant systemic treatment of breast cancer","authors":"Katarina Antunac","doi":"10.20471/lo.2019.47.01.04","DOIUrl":"https://doi.org/10.20471/lo.2019.47.01.04","url":null,"abstract":"When deciding on adjuvant radiotherapy in breast cancer patients, the decision is made based on the type of surgery (radical or conserving) and pathological report. In case systemic treatment is given before surgery, initial pathological report, which presents the backbone in decision making, is partly missing. Data from prospective randomized trials are lacking, and published retrospective data are inconsistent. Current guidelines are not clear for a large subset of patients. Also, guidelines and real-life data are often in discordance. This article aims to present literature data regarding the risk of locoregional relapse after neoadjuvant systemic treatment, the impact of radiotherapy on the risk of locoregional relapse, current clinical trial that is expected to give an answer in which subset of patients should adjuvant radiotherapy be performed and published clinical practice data.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.20471/lo.2019.47.01.04","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67598427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.20471/lo.2019.47.01.02
L. Novosel, D. Zadravec
percutaneous minimally invasive methods are gaining space in oncologic treatment algorithms. interventional radiology has a leading role in the last twenty years in developing percutaneous curative therapy for tumors of the parenchymal organs of the abdomen due to the precision of image-guided procedures. ablative technology uses thermal energy for tumor tissue destruction. compared to radiofrequency technology, microwave technology shows advantages in size of the liver tumors that can be ablated and the length of the procedure. compared to surgery, both ablative techniques, enable shorter postprocedural time to chemotherapy, hospital stay and recovery time, reduced complication rate, and easier secondary ablation in case of new or residual tumors. comparative advantages make these minimally invasive procedures, often the first choice in the treatment of hepatocellular carcinoma and liver metastases. Even though image-guided ablation is accepted in most european countries as a valid alternative to surgery in patients with unresectable hepatic tumors, currently, there is no algorithm for the use of this minimally invasive therapy in croatia. lack of clinical validation of thermal ablation in croatia is mostly due to a limited number of the interventional radiologist with such focus along with limited patient referrals despite the published data about the potential advantages, efficacy, and safety of this technology.
{"title":"Role of percutaneous image-guided ablation of malignant liver tumors: global trends and Croatian perspective","authors":"L. Novosel, D. Zadravec","doi":"10.20471/lo.2019.47.01.02","DOIUrl":"https://doi.org/10.20471/lo.2019.47.01.02","url":null,"abstract":"percutaneous minimally invasive methods are gaining space in oncologic treatment algorithms. interventional radiology has a leading role in the last twenty years in developing percutaneous curative therapy for tumors of the parenchymal organs of the abdomen due to the precision of image-guided procedures. ablative technology uses thermal energy for tumor tissue destruction. compared to radiofrequency technology, microwave technology shows advantages in size of the liver tumors that can be ablated and the length of the procedure. compared to surgery, both ablative techniques, enable shorter postprocedural time to chemotherapy, hospital stay and recovery time, reduced complication rate, and easier secondary ablation in case of new or residual tumors. comparative advantages make these minimally invasive procedures, often the first choice in the treatment of hepatocellular carcinoma and liver metastases. Even though image-guided ablation is accepted in most european countries as a valid alternative to surgery in patients with unresectable hepatic tumors, currently, there is no algorithm for the use of this minimally invasive therapy in croatia. lack of clinical validation of thermal ablation in croatia is mostly due to a limited number of the interventional radiologist with such focus along with limited patient referrals despite the published data about the potential advantages, efficacy, and safety of this technology.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.20471/lo.2019.47.01.02","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67598371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：